GAUDIUMIVFBSEGaudium IVF and Women Health LtdMediumNeutral
Announced Thu, 28 May · 19:58 IST

Standalone and Consolidated Audited Financial Results for the Quarter and Year ended March 31, 2026

Revenue Growth 20pctPat Growth 25pctResults View source PDF

GAUDIUMIVF · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.8%1-day move
₹116.79
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.8-3.8-5.7-7.6-9.4-9.5-6.9-5.1
Up moveDown movePending
AI summary

Gaudium IVF reported strong audited results for FY2026. On a consolidated basis, revenue grew 47.5% to Rs 10,435.70 Lakhs from Rs 7,072.40 Lakhs, while profit after tax rose 27.7% to Rs 2,448.85 Lakhs from Rs 1,917.73 Lakhs. Standalone revenue grew 21.3% to Rs 7,157.85 Lakhs with PAT at Rs 2,228.77 Lakhs. The company completed its IPO in February 2026, raising Rs 9,000.08 Lakhs from a fresh issue of 11.39 million shares at Rs 79 per share. IPO proceeds remain largely unutilized (Rs 8,131.20 Lakhs pending deployment). Auditors issued an unmodified (clean) opinion on both standalone and consolidated financial statements. The company operates in the healthcare/IVF segment and listed on NSE and BSE in February 2026.

Likely market impact

Strong revenue and profit growth, particularly on consolidated basis, along with successful IPO completion are positive signals for shareholders. The significant IPO proceeds awaiting deployment for new IVF centers could drive future growth. Clean audit opinion with no going concern issues supports financial stability.